- Home
- HRMY vs ROOT Comparison
HRMY vs ROOT Comparison
Compare HRMY & ROOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ROOT
- Stock Information
- Founded
- HRMY 2017
- ROOT 2015
- Country
- HRMY United States
- ROOT United States
- Employees
- HRMY N/A
- ROOT N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ROOT Property-Casualty Insurers
- Sector
- HRMY Health Care
- ROOT Finance
- Exchange
- HRMY Nasdaq
- ROOT Nasdaq
- Market Cap
- HRMY 1.6B
- ROOT 1.7B
- IPO Year
- HRMY 2020
- ROOT 2020
- Fundamental
- Price
- HRMY $34.05
- ROOT $147.42
- Analyst Decision
- HRMY Strong Buy
- ROOT Buy
- Analyst Count
- HRMY 8
- ROOT 7
- Target Price
- HRMY $52.88
- ROOT $120.83
- AVG Volume (30 Days)
- HRMY 701.6K
- ROOT 522.1K
- Earning Date
- HRMY 05-06-2025
- ROOT 05-07-2025
- Dividend Yield
- HRMY N/A
- ROOT N/A
- EPS Growth
- HRMY 13.13
- ROOT N/A
- EPS
- HRMY 2.62
- ROOT 3.16
- Revenue
- HRMY $744,852,000.00
- ROOT $1,271,000,000.00
- Revenue This Year
- HRMY $20.06
- ROOT $12.28
- Revenue Next Year
- HRMY $18.40
- ROOT $12.34
- P/E Ratio
- HRMY $13.10
- ROOT $46.68
- Revenue Growth
- HRMY 20.62
- ROOT 98.66
- 52 Week Low
- HRMY $26.47
- ROOT $34.04
- 52 Week High
- HRMY $41.61
- ROOT $181.14
- Technical
- Relative Strength Index (RSI)
- HRMY 69.53
- ROOT 56.82
- Support Level
- HRMY $29.82
- ROOT $125.00
- Resistance Level
- HRMY $30.61
- ROOT $157.75
- Average True Range (ATR)
- HRMY 1.12
- ROOT 11.32
- MACD
- HRMY 0.74
- ROOT 0.26
- Stochastic Oscillator
- HRMY 92.78
- ROOT 71.62
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.